683 Capital Management’s Zymeworks ZYME Stock Holding History

683 Capital Management’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-64,900	Closed	-$411K	–	275
2023 Q3	$411K	Hold	64,900	–	–	0.03%	108
2023 Q2	$561K	Sell	64,900 -125,100	-66%	-$1.12M	0.04%	113
2023 Q1	$1.72M	Sell	190,000 -100,000	-34%	-$872K	0.13%	123
2022 Q4	$2.28M	Buy	+290,000	New	+$2.04M	0.19%	95

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

683 Capital Management's ZYME Position: Q4 2023 in Review

683 Capital Management sold out of Zymeworks (ZYME) in Q4 2023, closing a stake of 64,900 shares — an estimated $411K sold.

683 Capital Management first reported a position in ZYME in Q4 2022 and held it in 4 quarters. The position peaked at $2.28M in Q4 2022. 157 funds tracked by Wall St. Rank hold ZYME as of Q4 2023.

683 Capital Management reported no remaining Zymeworks position as of Q4 2023 after selling out during the quarter.
683 Capital Management sold 64,900 Zymeworks shares in Q4 2023, an estimated $411K.
683 Capital Management first reported a position in Zymeworks in Q4 2022 and held it in 4 quarters.
683 Capital Management's Zymeworks position peaked at $2.28M in Q4 2022.
157 funds tracked by Wall St. Rank held Zymeworks as of Q4 2023.

Based on 683 Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.